NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ORTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.70▼$16.7050-Day Range$16.40▼$16.7052-Week Range$4.24▼$16.72VolumeN/AAverage Volume157,287 shsMarket Capitalization$380.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Orchard Therapeutics alerts: Email Address Orchard Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside49.7% Upside$25.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($4.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.54 out of 5 starsMedical Sector863rd out of 911 stocksBiotechnology Industry29th out of 33 stocks 3.2 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOrchard Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ORTX. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 26 news articles for Orchard Therapeutics this week, compared to 9 articles on an average week.Search Interest1 people have searched for ORTX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.90% of the stock of Orchard Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Orchard Therapeutics Stock (NASDAQ:ORTX)Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ORTX Stock News HeadlinesApril 19, 2024 | msn.comTDOT: I-40 West closed near Crab Orchard after vehicle overturnsApril 18, 2024 | msn.comMeghan Markle continues to lean into quiet luxury looks as American Riviera Orchard drops first productApril 19, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. April 18, 2024 | msn.comHijacking Meghan Markle's Orchard: Royal Fan Infiltrates Ex-Actress' Glossy Brand Website to Write Their 'Thoughts Are With Kate'April 18, 2024 | yahoo.comMeghan Markle’s A-List pals Mindy Kaling, Tracee Ellis Ross show off American Riviera Orchard jams she gifted to just 50 peopleApril 18, 2024 | msn.comMeghan Markle's American Riviera Orchard Might Benefit the Royal Family in This Unexpected WayApril 18, 2024 | msn.comConstruction, and traffic delays, to resume at Port Orchard's Bay Street roundaboutApril 18, 2024 | yahoo.comYes, That’s Meghan Markle’s Calligraphy on American Riviera Orchard’s LogoApril 19, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. April 17, 2024 | yahoo.comMan arrested in connection with 2023 Plum Orchard area homicideApril 17, 2024 | msn.comMeghan Markle’s first American Riviera Orchard product revealed, and fans are not impressedApril 17, 2024 | msn.comMeghan Markle’s American Riviera Orchard has a personal touch that went unnoticedApril 17, 2024 | msn.comMeghan Markle urged to 'expand her outreach' if American Riviera Orchard is to succeedApril 16, 2024 | msn.comMeghan Markle pumps up the jam as she introduces American Riviera Orchard jelly, sends it to influencer palsApril 16, 2024 | msn.comMeghan Markle's lifestyle brand American Riviera Orchard unleashes first productApril 16, 2024 | msn.comDuchess Meghan teases first product from American Riviera Orchard lifestyle brandApril 16, 2024 | msn.comMeghan Markle’s American Riviera Orchard Line: All We Know So FarApril 16, 2024 | msn.comMeghan Markle's American Riviera Orchard products: Strawberry jam and beyondApril 16, 2024 | msn.comMeghan Markle's American Riviera Orchard Just Released Its First Product — & It's Quite ExclusiveApril 16, 2024 | msn.comMeghan: Jam the first product released from Duchess of Sussex's new lifestyle brand American Riviera OrchardApril 16, 2024 | mirror.co.ukEverything we know about American Riviera Orchard as Meghan Markle teases productsApril 16, 2024 | yahoo.comMeghan Markle Reveals First American Riviera Orchard ProductApril 16, 2024 | msn.comMeghan, Duchess of Sussex unveils first product from American Riviera OrchardApril 16, 2024 | mirror.co.ukMeghan Markle gives sneak peek at products from her new brand American Riviera OrchardApril 16, 2024 | mirror.co.ukMeghan Markle finally launches first long-awaited product from American Riviera OrchardApril 16, 2024 | msn.comMeghan Markle unveils first American Riviera Orchard jam, sends it to influencer palsApril 14, 2024 | msn.comFermanagh 0-9 Armagh 3-11: 'We looked hungry' - Orchard boss Kieran McGeeneySee More Headlines Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$34.00 Low Stock Price Target$16.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-333.90% Pretax Margin-334.54% Return on Equity-74.94% Return on Assets-33.51% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.98 Sales & Book Value Annual Sales$22.66 million Price / Sales16.77 Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book2.16Miscellaneous Outstanding Shares22,760,000Free Float22,099,000Market Cap$380.09 million OptionableOptionable Beta0.55 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Hubert Baburaj Gaspar M.D. (Age 61)Ph.D., CEO, Member of Scientific Advisory Board & Executive Director Comp: $901.42kMr. Frank Edward Thomas (Age 55)President & COO Comp: $763.95kDr. Nicoletta Loggia Ph.D.R.Ph., Chief Technical OfficerDr. Fulvio Mavilio Ph.D.Chief Scientific OfficerMs. Renee T. LeckHead of Investor RelationsBenjamin NavonDirector of Corporate CommunicationsMr. John CerioChief Human Resource OfficerMr. Robin KenselaarSenior VP & GM of EMEA Commercial OperationsMr. Braden ParkerChief Commercial OfficerDr. Leslie Meltzer Ph.D.Chief Medical OfficerMore ExecutivesKey CompetitorsSolid BiosciencesNASDAQ:SLDBHarpoon TherapeuticsNASDAQ:HARPUroGen PharmaNASDAQ:URGNShattuck LabsNASDAQ:STTKCorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 137,520 shares on 3/1/2024Ownership: 0.604%Gamco Investors INC. ET ALBought 15,188 shares on 2/15/2024Ownership: 0.067%GTS Securities LLCBought 15,000 shares on 2/15/2024Ownership: 0.066%Vident Advisory LLCBought 11,270 shares on 2/15/2024Ownership: 0.050%Citadel Advisors LLCSold 1,200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions ORTX Stock Analysis - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 12-month price objectives for Orchard Therapeutics' shares. Their ORTX share price targets range from $16.00 to $34.00. On average, they predict the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $1.49. The company earned $1.24 million during the quarter, compared to the consensus estimate of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 74.94% and a negative net margin of 333.90%. When did Orchard Therapeutics' stock split? Orchard Therapeutics's stock reverse split on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? Orchard Therapeutics (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ORTX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.